JAK2 and chronic kidney disease: In addition, isoliquiritigenin improved renal inflammation by inhibiting the Janus kinase 2 (JAK2)/STAT3 signaling pathways in CKD rats (Figure 1; Table 1) (Atteia et al., 2023; Zhang et al., 2024).